Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iohexol
Drug ID BADD_D01180
Description Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Indications and Usage Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Marketing Status approved
ATC Code V08AB02
DrugBank ID DB01362
KEGG ID D01817
MeSH ID D007472
PubChem ID 3730
TTD Drug ID D02BLO
NDC Product Code 43228-100; 0407-1413; 71806-141; 0407-1414; 0407-1416; 0407-1415; 0407-1401; 0407-1411; 0407-1412; 65072-0801; 54702-501
UNII 4419T9MX03
Synonyms Iohexol | Iohexol 350 | Nycodenz | Compound 545 | Exypaque | Omnipaque
Chemical Information
Molecular Formula C19H26I3N3O9
CAS Registry Number 66108-95-0
SMILES CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Henoch-Schonlein purpura10.02.02.004; 01.01.04.001; 24.07.06.003; 23.06.01.0020.007113%Not Available
Hepatitis acute09.01.07.0050.007113%Not Available
Hepatitis fulminant11.07.01.003; 09.01.07.0070.007113%Not Available
Hostility19.05.01.003--Not Available
Hyperaemia24.03.02.0020.021340%Not Available
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hyperhidrosis08.01.03.028; 23.02.03.0040.257505%
Hyperpyrexia08.05.02.0020.010670%Not Available
Hyperreflexia17.02.01.002--Not Available
Hypersensitivity10.01.03.0031.131029%
Hypertension24.08.02.0010.135866%
Hypertensive crisis24.08.01.0010.014227%Not Available
Hyperthermia12.05.01.002; 08.05.01.0010.017783%Not Available
Hyperthyroidism14.11.01.011; 05.02.02.0010.028454%
Hypertonia17.05.02.001; 15.05.04.0070.007113%Not Available
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.170721%Not Available
Hypopnoea22.02.01.0210.024897%Not Available
Hypotension24.06.03.0020.432494%
Hypothermia12.05.03.001; 08.05.01.0030.017783%
Hypotonia17.05.02.002; 15.05.04.0080.014227%Not Available
Hypoxia22.02.02.0030.032010%
Immune system disorder10.02.01.001--Not Available
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.0110.014227%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.0010.026320%Not Available
Injection site extravasation12.07.03.002; 08.02.03.0020.128752%Not Available
Injection site oedema08.02.03.024; 12.07.03.0240.021340%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.078959%Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.0130.007113%Not Available
Injection site rash23.03.13.010; 12.07.03.032; 08.02.03.032--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene